Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

DBV Technologies

DBV Technologies
2002 FOUNDED
PUBLIC STATUS
301-400 EMPLOYEES
DBV STOCK SYMBOL
$15.63 SHARE PRICE (As of Tuesday Closing)
Description

DBV Technologies SA is a biotechnology company that provides therapy for food and pediatric allergy patients. The company focuses on discovering, developing, manufacturing, and commercializing treatments for severe allergies in the United States and other global markets. DBV's method of delivering biologically active compounds to the immune system is through self-administered and noninvasive products. The company also explores potential applications of its platform in vaccines and other immune diseases.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
PAR
Primary Office
  • 177-181 Avenue Pierre Brossolette
  • 92120 Montrouge
  • France

+33 01 00 00 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore DBV Technologies’s full profile, request a free trial.

DBV Technologies Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$8.64 - $32.28 $735M $15.63 -$6.35 234K 47M

DBV Technologies Financials Summary

In Thousands,
USD
TTM
30-Jun-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 469,146 135,824 1,027,095 1,381,975
Revenue 0 0 0 0
EBITDA (190,378) (192,787) (160,208) (126,853)
Net Income (198,266) (195,981) (166,563) (126,688)
Total Assets 212,234 196,464 213,315 302,364
Total Debt 29,306 2,836 4,979 4,880
Public Fundamental Data provided by Morningstar, Inc. disclaimer

DBV Technologies Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore DBV Technologies‘s full profile, request access.

Request full access to PitchBook

DBV Technologies Competitors (19)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aimmune Therapeutics Corporate Backed or Acquired Brisbane, CA 000 00000 00000000000 00000
000000 Venture Capital-Backed San Diego, CA 0 00.000 0000000000 0 00.000
000000 Formerly VC-backed Lyon, France 000 000.00 00000000 000.00
0000000 Formerly VC-backed Summit, NJ 0000 000.00 000000&0 000.00
000000000 00000000 Venture Capital-Backed Rockville, MD 00 000.00 0000000000 0 000.00
To view this company’s complete list of competitors, request access »

DBV Technologies Executive Team (17)

Name Title Board
Seat
Contact
Info
Daniel Tassé Chief Executive Officer
David Schilansky Chief Financial Officer & Deputy CEO
Laurent Martin Ph.D Executive & Deputy CEO
Sébastien Robitaille Chief of Staff & Interim Chief Financial Officer
Magali Richard Ph.D Chief Strategy Officer

3 Former Executives

You’re viewing 5 of 17 executives. Get the full list »

DBV Technologies Board Members (11)

Name Representing Role Since Contact
Info
Daniel Soland Self Board Member 000 0000
Maïlys Ferrère Self Board Member 000 0000
Michael Goller DBV Technologies Board Member 000 0000
Michel De Rosen DBV Technologies Chairman & Board Member 000 0000
Torbjörn Bjerke MD Self Board Member 000 0000

6 Former Board Members

You’re viewing 5 of 11 board members. Get the full list »